What does the cutting-edge of digital health look like? Which innovations are on the cusp of becoming a mainstream reality and who is it that is driving this advancement?
IQVIA’s Murray Aitken examines the potential for savings from a new wave of oncology biosimilars – but says payers have to invest in education and incentives to maximise uptake.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.